Skip to main content
The Globe and Mail
Support Quality Journalism
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); }
TSX Venture Real-Time Last Sale CAD
Today's Change
Volume
Price Quote as of

More stories below advertisement

Latest Press Releases

RepliCel Q3 2020 Management Update
- GlobeNewswire - Mon Sep 14, 4:45PM CDT
GlobeNewswire - CMTX
Mon Sep 14, 4:45PM CDT
RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to provide an update to shareholders from its Board and Management represented by President and CEO, Mr. R. Lee Buckler.
RepliCel Announces its Incoming Board of Directors
- PR Newswire - Mon Dec 23, 5:00AM CST
PR Newswire - CMTX
Mon Dec 23, 5:00AM CST
Successful Annual General Meeting Confirms Director Slate for 2020
RepliCel Announces its Incoming Board of Directors
- PR Newswire - Mon Dec 23, 5:00AM CST
PR Newswire - PRNW
Mon Dec 23, 5:00AM CST
Successful Annual General Meeting Confirms Director Slate for 2020
RepliCel Provides 2019 Year-End Update
- PR Newswire - Tue Nov 26, 5:00AM CST
PR Newswire - CMTX
Tue Nov 26, 5:00AM CST
Notable Milestones for the Company's Programs
RepliCel Provides 2019 Year-End Update
- PR Newswire - Tue Nov 26, 5:00AM CST
PR Newswire - PRNW
Tue Nov 26, 5:00AM CST
Notable Milestones for the Company's Programs
Clinical Data Published from RepliCel's Skin Rejuvenation Study
- PR Newswire - Tue Sep 24, 5:00AM CDT
PR Newswire - PRNW
Tue Sep 24, 5:00AM CDT
A paper entitled, "Autologous Cell Therapy for Aged Human Skin: A Randomized, Placebo-Controlled, Phase-I Study", has been published summarizing the data from RepliCel's clinical trial of RCS-01
Clinical Data Published from RepliCel's Skin Rejuvenation Study
- CNW Group - Tue Sep 24, 5:00AM CDT
CNW Group - CMTX
Tue Sep 24, 5:00AM CDT
A paper entitled, "Autologous Cell Therapy for Aged Human Skin: A Randomized, Placebo-Controlled, Phase-I Study", has been published summarizing the data from RepliCel's clinical trial of RCS-01
Clinical Data Published from RepliCel's Skin Rejuvenation Study
- PR Newswire - Tue Sep 24, 5:00AM CDT
PR Newswire - CMTX
Tue Sep 24, 5:00AM CDT
A paper entitled, "Autologous Cell Therapy for Aged Human Skin: A Randomized, Placebo-Controlled, Phase-I Study", has been published summarizing the data from RepliCel's clinical trial of RCS-01
RepliCel's Partner, YOFOTO (China) Health, Unveils its Inaugural Cell Therapy Manufacturing Facility in China
- PR Newswire - Tue Sep 10, 5:00AM CDT
PR Newswire - CMTX
Tue Sep 10, 5:00AM CDT
YOFOTO (China) Health Now Commissioning its Manufacturing Facility in Preparation for Technology Transfer of Skin and Tendon Product Manufacturing and Applications for Clinical Trials
RepliCel's Partner, YOFOTO (China) Health, Unveils its Inaugural Cell Therapy Manufacturing Facility in China
- PR Newswire - Tue Sep 10, 5:00AM CDT
PR Newswire - PRNW
Tue Sep 10, 5:00AM CDT
YOFOTO ( China ) Health Now Commissioning its Manufacturing Facility in Preparation for Technology Transfer of Skin and Tendon Product Manufacturing and Applications for Clinical Trials

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2020.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies